refine: a real-world analysis of regorafenib in patients with unresectable hcc
Published 1 year ago • 109 plays • Length 2:52Download video MP4
Download video MP3
Similar videos
-
1:21
oreios: real-world registry of patients with unresectable hcc
-
2:53
renobate: investigating regorafenib plus nivolumab as 1st-line therapy for unresectable hcc
-
1:09
survival benefit confirmed in real-life analysis of second-line regorafenib in hcc
-
4:32
first-line regorafenib 80mg/day with pembrolizumab in advanced hcc
-
1:10
real life analysis shows regorafenib improves survival upon progression on sorafenib in hcc
-
3:18
rationale and study design of a phase iii study of sorafenib and sbrt for hepatocellular carcinoma
-
3:10
regorafenib in refractory biliary tract cancer
-
1:08
dr. bendell on fda approval of regorafenib in liver cancer
-
5:26
hcc whiteboard #1: the epidemiology of hepatocellular carcinoma and current standard of care
-
1:03
dr. musher discusses the role of regorafenib in advanced hcc
-
5:31
practical advice for using regorafenib
-
1:09
improving guidance on choice of first-line therapy for patients with hcc
-
2:01
qol analyses from rationale-301 of tislelizumab vs sorafenib in hcc
-
2:28
nrg/rtog 1112: sorafenib vs sbrt followed by sorafenib in hcc
-
3:48
clinical experience with regorafenib in hcc
-
1:28
dr. o’connor on real-world results with regorafenib in mcrc
-
7:01
global use of regorafenib in hcc
-
7:46
clinical use of regorafenib in mhcc
-
0:42
dr. bendell on the future of regorafenib for patients with crc